![Alwyn Mwinga](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Alwyn Mwinga
Direktor/Vorstandsmitglied bei Drugs for Neglected Diseases initiative
Aktive Positionen von Alwyn Mwinga
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Drugs for Neglected Diseases initiative
![]() Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Alwyn Mwinga
Ausbildung von Alwyn Mwinga
University of London | Graduate Degree |
University of Zambia | Graduate Degree |
Statistik
International
Schweiz | 2 |
Vereinigtes Königreich | 2 |
Sambia | 2 |
Operativ
Graduate Degree | 2 |
Director/Board Member | 1 |
Sektoral
Consumer Services | 3 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Drugs for Neglected Diseases initiative
![]() Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | Health Technology |
- Börse
- Insiders
- Alwyn Mwinga
- Erfahrung